ACR: CMS rule on Medicare drug price negotiation could have ‘unintended consequences’

A proposed CMS rule codifying the Medicare Drug Price Negotiation Program could result in “unintended consequences” for physician practices and treatment access, according to a statement from the American College of Rheumatology.In its statement, addressed to CMS Administrator Mehmet Oz, MD, the ACR warned that the new round of Medicare drug price negotiations may

Raccontata dahealio.com